» Articles » PMID: 26431346

Risk Factors for Central Lymph Node Metastasis in CN0 Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis

Overview
Journal PLoS One
Date 2015 Oct 3
PMID 26431346
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Central lymph node metastasis (CLNM) is common in papillary thyroid carcinoma (PTC). Prophylactic central lymph node dissection (PCLND) for patients with clinically negative central compartment lymph nodes (CN0) remains controversial. The phrase "clinically negative" is used to indicate that patients exhibited no clinical evidence of CLNM by ultrasonography (US) or computerized tomography (CT) preoperatively. In this study, we analyze the risk factors for CLNM in CN0 patients.

Methods: The PUBMED and SCIE databases were systematically searched for works published through January 31, 2015. All of the patients included in this study underwent thyroidectomy+PCLND. Revman 5.3 software was used to analyze the data.

Results: Twenty studies and 9084 patients were included in this meta-analysis. The following variables were associated with an increased risk of CLNM in CN0 patients: age < 45 years (OR = 1.59, 95% CI = 1.42-1.78, p<0.00001), male sex (OR = 1.95, 95% CI = 1.63-2.32, p<0.00001), multifocality (OR = 1.43, 95% CI = 1.22-1.67, p<0.00001), tumor size > 2 cm for PTC patients (OR = 2.98, 95% CI 2.08-4.28, p<0.00001) or tumor size > 0.5 cm for papillary thyroid microcarcinoma (PTMC) patients (OR = 2.30, 95% CI = 1.71-3.09, p<0.00001), location of the primary tumor in the central area and low pole (OR = 1.86, 95% CI = 1.48-2.33, p<0.00001), lymphovascular invasion (OR = 4.35, 95% CI = 2.24-8.46, p<0.0001), extrathyroidal extension (OR = 2.27, 95% CI = 1.76-2.94, p<0.00001), and capsular invasion (OR = 1.72, 95% CI = 1.39-2.41, p<0.00001). PTC (tumor size > 1 cm) exhibited a higher risk factor associated with CLNM than PTMC (tumor size < 1 cm) (OR = 2.83, 95% CI = 2.15-3.72, p<0.00001). Bilateral tumors (OR = 1.21, 95% CI = 0.92-1.58, p = 0.17) and lymphocytic thyroiditis (OR = 0.88, 95% CI = 0.71-1.09, p = 0.25) had no association with CLNM in CN0 patients.

Conclusions: Our systematic review identified several clinical features associated with CLNM in CN0 patients, including age, sex, multifocality, size, location, lymphovascular invasion, capsular invasion, and extrathyroidal extension. These factors should guide the application of PCLND in CN0 patients.

Citing Articles

Development and validation of a risk score model for patient stratification and personalized management of papillary thyroid cancer.

Guo H, Shen N, Hu Y, Hao X, Zhang H, Huang T Gland Surg. 2024; 13(11):2116-2127.

PMID: 39678428 PMC: 11635556. DOI: 10.21037/gs-24-344.


Construction and validation of a diagnostic model for high-risk papillary thyroid microcarcinoma.

Liang Y, Fan E, Zhang J, Xu T, Song J, Huang F Front Endocrinol (Lausanne). 2024; 15:1431584.

PMID: 39444456 PMC: 11496096. DOI: 10.3389/fendo.2024.1431584.


Prognostic factors for aggressiveness in subcentimeter papillary thyroid carcinoma: impact of tumor size and lymph node metastases.

Kayhan Y, Azizova L, Yilmaz M, Bakis M, Kefeli M, Kan E Arch Endocrinol Metab. 2024; 68:e230422.

PMID: 39420875 PMC: 11326733. DOI: 10.20945/2359-4292-2023-0422.


Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings.

Ito Y, Miyauchi A Eur Thyroid J. 2024; 13(5).

PMID: 39213599 PMC: 11466271. DOI: 10.1530/ETJ-24-0196.


Prediction of lateral neck metastasis in patients with papillary thyroid cancer with suspicious lateral lymph ultrasonic imaging based on central lymph node metastasis features.

Xu Y, Zhang C Oncol Lett. 2024; 28(4):472.

PMID: 39211301 PMC: 11358722. DOI: 10.3892/ol.2024.14605.


References
1.
Grebe S, Hay I . Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996; 5(1):43-63. View

2.
Londero S, Krogdahl A, Bastholt L, Overgaard J, Pedersen H, Hahn C . Papillary thyroid carcinoma in Denmark, 1996-2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. Thyroid. 2014; 25(1):78-84. DOI: 10.1089/thy.2014.0294. View

3.
Rahbari R, Zhang L, Kebebew E . Thyroid cancer gender disparity. Future Oncol. 2010; 6(11):1771-9. PMC: 3077966. DOI: 10.2217/fon.10.127. View

4.
Jiang L, Chen C, Tan Z, Lu X, Hu S, Wang Q . Clinical Characteristics Related to Central Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma: A Retrospective Study of 916 Patients. Int J Endocrinol. 2014; 2014:385787. PMC: 4158156. DOI: 10.1155/2014/385787. View

5.
Tuttle R, Haddad R, Ball D, Byrd D, Dickson P, Duh Q . Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014; 12(12):1671-80. DOI: 10.6004/jnccn.2014.0169. View